STOCK TITAN

[6-K] CureVac N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

CureVac N.V. (CVAC) filed a Form 6-K to notify investors that it issued a press release on June 24, 2025 detailing the voting results from its Annual General Meeting of shareholders. No financial performance metrics, strategic transactions, or operational updates were included in the filing. The company also clarified that the information, including Exhibit 99.1 (the press release), is furnished—not filed—and therefore is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other SEC filings.

CureVac N.V. (CVAC) ha presentato un Modulo 6-K per informare gli investitori di aver rilasciato un comunicato stampa il 24 giugno 2025, contenente i risultati delle votazioni dell'Assemblea Generale Annuale degli azionisti. Nel documento non sono stati inclusi dati sulle performance finanziarie, transazioni strategiche o aggiornamenti operativi. La società ha inoltre precisato che le informazioni, incluso l'Allegato 99.1 (il comunicato stampa), sono fornite e non depositate, pertanto non sono soggette alle responsabilità previste dalla Sezione 18 del Exchange Act né incorporate per riferimento in altri documenti SEC.

CureVac N.V. (CVAC) presentó un Formulario 6-K para notificar a los inversores que emitió un comunicado de prensa el 24 de junio de 2025 detallando los resultados de la votación de su Junta General Anual de accionistas. No se incluyeron métricas de desempeño financiero, transacciones estratégicas ni actualizaciones operativas en la presentación. La compañía también aclaró que la información, incluido el Anexo 99.1 (el comunicado de prensa), es proporcionada, no presentada, y por lo tanto no está sujeta a las responsabilidades de la Sección 18 de la Ley de Intercambio ni incorporada por referencia en otros documentos de la SEC.

CureVac N.V. (CVAC)는 2025년 6월 24일에 주주 연례 총회 투표 결과를 상세히 알리는 보도자료를 발표했음을 투자자들에게 알리기 위해 Form 6-K를 제출했습니다. 제출서에는 재무 성과 지표, 전략적 거래 또는 운영 업데이트는 포함되지 않았습니다. 회사는 또한 정보(보도자료인 Exhibit 99.1 포함)가 제출된 것이 아니라 제공된 것으로, 따라서 Exchange Act 섹션 18의 책임 대상이 아니며 다른 SEC 제출 문서에 참조로 포함되지 않는다고 명확히 했습니다.

CureVac N.V. (CVAC) a déposé un formulaire 6-K pour informer les investisseurs qu'elle a publié un communiqué de presse le 24 juin 2025 détaillant les résultats des votes de son assemblée générale annuelle des actionnaires. Aucun indicateur de performance financière, transaction stratégique ou mise à jour opérationnelle n’a été inclus dans le dépôt. La société a également précisé que les informations, y compris l’Exhibit 99.1 (le communiqué de presse), sont fournies et non déposées, et ne sont donc pas soumises aux responsabilités de la Section 18 du Exchange Act ni incorporées par référence dans d’autres dépôts auprès de la SEC.

CureVac N.V. (CVAC) reichte ein Formular 6-K ein, um Investoren darüber zu informieren, dass am 24. Juni 2025 eine Pressemitteilung mit den Abstimmungsergebnissen der jährlichen Hauptversammlung der Aktionäre veröffentlicht wurde. Finanzielle Leistungskennzahlen, strategische Transaktionen oder operative Updates waren in der Einreichung nicht enthalten. Das Unternehmen stellte außerdem klar, dass die Informationen, einschließlich Anlage 99.1 (die Pressemitteilung), bereitgestellt und nicht eingereicht sind und daher nicht den Haftungsbestimmungen von Abschnitt 18 des Exchange Act unterliegen und nicht durch Verweis in andere SEC-Einreichungen aufgenommen werden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine governance disclosure; no direct financial impact disclosed.

This 6-K merely furnishes notice that CureVac released AGM voting outcomes. Without the actual vote breakdown—such as director re-election percentages or approval of compensation policies—investors cannot gauge shifts in shareholder sentiment. Given the absence of material financial data or strategy updates, the filing is procedural. Its primary value is confirming that governance resolutions were put to vote and that management complied with foreign-issuer disclosure norms.

CureVac N.V. (CVAC) ha presentato un Modulo 6-K per informare gli investitori di aver rilasciato un comunicato stampa il 24 giugno 2025, contenente i risultati delle votazioni dell'Assemblea Generale Annuale degli azionisti. Nel documento non sono stati inclusi dati sulle performance finanziarie, transazioni strategiche o aggiornamenti operativi. La società ha inoltre precisato che le informazioni, incluso l'Allegato 99.1 (il comunicato stampa), sono fornite e non depositate, pertanto non sono soggette alle responsabilità previste dalla Sezione 18 del Exchange Act né incorporate per riferimento in altri documenti SEC.

CureVac N.V. (CVAC) presentó un Formulario 6-K para notificar a los inversores que emitió un comunicado de prensa el 24 de junio de 2025 detallando los resultados de la votación de su Junta General Anual de accionistas. No se incluyeron métricas de desempeño financiero, transacciones estratégicas ni actualizaciones operativas en la presentación. La compañía también aclaró que la información, incluido el Anexo 99.1 (el comunicado de prensa), es proporcionada, no presentada, y por lo tanto no está sujeta a las responsabilidades de la Sección 18 de la Ley de Intercambio ni incorporada por referencia en otros documentos de la SEC.

CureVac N.V. (CVAC)는 2025년 6월 24일에 주주 연례 총회 투표 결과를 상세히 알리는 보도자료를 발표했음을 투자자들에게 알리기 위해 Form 6-K를 제출했습니다. 제출서에는 재무 성과 지표, 전략적 거래 또는 운영 업데이트는 포함되지 않았습니다. 회사는 또한 정보(보도자료인 Exhibit 99.1 포함)가 제출된 것이 아니라 제공된 것으로, 따라서 Exchange Act 섹션 18의 책임 대상이 아니며 다른 SEC 제출 문서에 참조로 포함되지 않는다고 명확히 했습니다.

CureVac N.V. (CVAC) a déposé un formulaire 6-K pour informer les investisseurs qu'elle a publié un communiqué de presse le 24 juin 2025 détaillant les résultats des votes de son assemblée générale annuelle des actionnaires. Aucun indicateur de performance financière, transaction stratégique ou mise à jour opérationnelle n’a été inclus dans le dépôt. La société a également précisé que les informations, y compris l’Exhibit 99.1 (le communiqué de presse), sont fournies et non déposées, et ne sont donc pas soumises aux responsabilités de la Section 18 du Exchange Act ni incorporées par référence dans d’autres dépôts auprès de la SEC.

CureVac N.V. (CVAC) reichte ein Formular 6-K ein, um Investoren darüber zu informieren, dass am 24. Juni 2025 eine Pressemitteilung mit den Abstimmungsergebnissen der jährlichen Hauptversammlung der Aktionäre veröffentlicht wurde. Finanzielle Leistungskennzahlen, strategische Transaktionen oder operative Updates waren in der Einreichung nicht enthalten. Das Unternehmen stellte außerdem klar, dass die Informationen, einschließlich Anlage 99.1 (die Pressemitteilung), bereitgestellt und nicht eingereicht sind und daher nicht den Haftungsbestimmungen von Abschnitt 18 des Exchange Act unterliegen und nicht durch Verweis in andere SEC-Einreichungen aufgenommen werden.

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number: 001-39446

 

 

 

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x         Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨          No x

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨          No x

 

 

 

 

 

 

On June 24, 2025, CureVac N.V. (the “Company”) issued a press release announcing the voting results of the Company’s annual general meeting of shareholders.

 

The information included in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CureVac N.V.
  (Registrant)
   
Date: June 24, 2025 By: /s/ Alexander Zehnder
    Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT NO.   DESCRIPTION
99.1   CureVac N.V. Press Release dated June 24, 2025

 

 

 

FAQ

What did CureVac (CVAC) disclose in its June 24 2025 Form 6-K?

The company announced it issued a press release reporting AGM voting results.

Does the 6-K include CureVac’s financial performance or earnings data?

No. The filing contains no financial metrics or earnings information.

Is the information in CureVac’s 6-K considered "filed" under the Exchange Act?

No. The company states the information is "furnished," not "filed," avoiding Section 18 liability.

Where can investors find the detailed AGM voting results for CVAC?

The results are in Exhibit 99.1, CureVac’s press release dated June 24 2025.
Curevac B.V.

NASDAQ:CVAC

CVAC Rankings

CVAC Latest News

CVAC Latest SEC Filings

CVAC Stock Data

1.22B
96.00M
45.26%
18.01%
1.74%
Biotechnology
Healthcare
Link
Germany
Tübingen